Progressive Familial Intrahepatic Cholestasis Clinical Trials

31 clinical trials for Progressive Familial Intrahepatic Cholestasis across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China — RECRUITING
• A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea — RECRUITING
• Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU) — RECRUITING · PHASE4
• DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE — RECRUITING · NA
• A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) — RECRUITING
• Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) — RECRUITING
• Prospective Analysis of the Treatment of Progressive Familial Intrahepatic Cholestasis (TreatFIC) — RECRUITING
• NAtural Course and Prognosis of PFIC and Effect of Biliary Diversion — RECRUITING
• Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis — RECRUITING
• Familial Intrahepatic Cholestasis-related Genes Associated with Disease Susceptibility in Hepato-biliary Cancers — RECRUITING
• Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis — TERMINATED
• An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC) — COMPLETED · PHASE3
• A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). — COMPLETED · PHASE2
• Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC — COMPLETED · PHASE3
• A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) — COMPLETED · PHASE3
• Baby Detect : Genomic Newborn Screening — COMPLETED
• Progressive Familial Intrahepatic Cholestasis in Indian Children - Establishing an Indian PFIC Registry — OTHER
• A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 — COMPLETED · PHASE1
• An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects — COMPLETED · PHASE1
• A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) — COMPLETED · PHASE3
• Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis — COMPLETED · PHASE2
• Pruritus in chronic cholestatic liver diseases in children and adolescents: The need for a more nuanced classification. — OTHER
• Gastrostomy-Biliary Diversion: Innovative Management for Bile Canalicular Transport Disorders — OTHER · NA
• A LONG-TERM SAFETY STUDY OF MARALIXIBAT, AN APICAL SODIUM DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN SUBJECTS WHO PREVIOUSLY PARTICIPATED IN A MARALIXIBAT STUDY — COMPLETED
• AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF MARALIXIBAT IN THE TREATMENT OF SUBJECTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) — COMPLETED
• RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MARALIXIBAT IN THE TREATMENT OF SUBJECTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) ¿ MARCH-PFIC — COMPLETED · PHASE3
• Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease — COMPLETED
• A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) — WITHDRAWN · PHASE3
• AN OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM EFFICACY AND SAFETY OF A4250 IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TYPES 1 AND 2 (PEDFIC 2). — COMPLETED
• A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY TO DEMONSTRATE EFFICACY AND SAFETY OF A4250 IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TYPES 1 AND 2 (PEDFIC 1) — COMPLETED · PHASE3
• OPEN LABEL STUDY OF THE EFFICACY AND LONG TERM SAFETY OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS — COMPLETED

Refine this search